

3Q24 | Earnings presentation



Disclaimer

This is a brief presentation of the main highlights of the quarterly information of Hospital Mater Dei SA (“Mater Dei” or “Company”) for the quarter and nine months period ended on September 30, 2024 (“Financial Statements”).

This presentation has been summarized and is not intended to be complete. The Company's shareholders and potential investors must always read this presentation together with the Quarterly Information published in the IR and CVM website.

This presentation was prepared for informational purposes only and should not be taken as a request for an offer to buy or sell any securities and should not be treated as an investment recommendation.

No statement, express or otherwise, is made regarding the accuracy, certainty or comprehensiveness of the information contained in this presentation. The Company's past performance is not an indicative of future results. This presentation should not be used as the basis for any agreement or contract.

Information regarding the Mater Dei Hospital, its activities, economic and financial position and the risks inherent to its activities, as well as its financial statements, can be found on the world wide web, on the Mater Dei website (<https://ri.materdei.com.br/en>).

Porto Dias Divestment Closing

- Divestiture concluded on September 16th, 2024;
- Mater Dei received BRL 401.3 million in local currency and 27,272,728 shares issued by the Company, of which 24,660,627 shares were cancelled;
- The operation strengthens financial discipline, improvement in receivables, working capital and net indebtedness;

Opening of Nova Lima unit

- Opening on August 23rd, 2024;
- Fourth unit of the Company in the metro region of Belo Horizonte;
- It has capacity for 117 beds and offers a broad range of medical specialties;
- 24-hours pediatric, adult and obstetric emergency room, a diagnostic medicine service, an infusion center and clinical and surgical admission.



Clinical Excellence Yearbook

- Disclosure for the second year running;
- presents the Company's results for 2023 and brings clinical indicators compared with the data released by ANAHP in the same year;
- Audited by an external source;
- Reinforces the excellence in patient care and safety.





Sustainability Report




- Rede Mater Dei fifth Sustainability Report;
- Reinforcing its commitment to the ESG aspect;
- The report was drawn up following the international guidelines established by the GRI.

Operational highlights

Quarterly avg. operational beds and occupancy rate




% change in number of patients-day versus 3Q23




Revenue

Average Ticket – BRL Mm / used beds




Net Revenue – R\$ Mm




Costs and expenses

Costs of services provided – BRL Mm




Adjusted General and Adm. Expenses – BRL Mm



Adjusted EBITDA


EBITDA and EBITDA margin – R\$ Mm




| EBITDA reconciliation BRL million | 3Q24 | 9M24 |
|--|--------------|----------------|
| EBIT | 153.7 | (386.5) |
| Depreciation and amortization | 27.2 | 82.2 |
| EBITDA | 180.9 | (304.3) |
| <i>% of net revenue</i> | <i>31.7%</i> | <i>-17.5%</i> |
| Divestment of assets | 10.1 | 754.3 |
| EBITDA adjusted with HPD's sale | 191.0 | 449.9 |
| <i>% of net revenue</i> | <i>35.5%</i> | <i>25.9%</i> |
| Nova Lima preoperational | 4.3 | 5.3 |
| Contingencies reversal | (74.0) | (74.0) |
| Adjusted EBITDA | 121.3 | 381.2 |
| <i>% of net revenue</i> | <i>21.3%</i> | <i>21.9%</i> |

Net income and Cash Flow


Adjusted net income and net margin - BRL Mm



Cash Flow - BRL Mm




DSO, DPO and DIO¹ - days




1. Days sales outstanding (DSO) calculated as Accounts Receivable / (Gross Revenue LTM/365); days payables outstanding (DPO) calculated as (Suppliers - Goods of a permanent nature) / (Costs and Expenses - Personnel and Depreciation LTM/365); and days of inventory outstanding (DIO) calculated as average Inventories / (Materials and Medicines LTM/365).

Debt and Leverage


Net debt / EBITDA



Debt payment schedule³ - BRL Mm



Average cost of debt and indexation



1. According to the covenant of the 1st debenture issue of the Company: considering the sum of the balances of loans, financing and debentures net of all derivative financial instruments (current and noncurrent). It does not consider liabilities for lease and acquisition of companies payable. 2. Cash and cash equivalent and Financials. 3. Transaction costs are not included


Q&A



For questions via audio, please raise your hand to join the line. When announced to ask the question, your microphone will be enabled. We ask for all the questions to be made at once.



If you prefer, write your question directly in the Q&A icon at the bottom of the screen



+

MaterDei

Rede de Saúde

+

MaterDei

Hospital Santo Agostinho

+

MaterDei

Hospital Betim-Contagem

+

MaterDei

Hospital Nova Lima

+

MaterDei

Hospital Contorno

+

MaterDei

Hospital Salvador

+

MaterDei

Rede de Saúde

A3Data

+

MaterDei

Rede de Saúde

SANTA GENOVEVA

+

MaterDei

Rede de Saúde

CD

+

MaterDei

Rede de Saúde

hospital santa clara

+

MaterDei

Rede de Saúde

emec

+

MaterDei

Rede de Saúde

HOSPITAL PREMIUM

CENTRO DE TERAPIA AVANÇADA

TUDO
PRA
VOCÊ
FICAR
BEM

MATERDEI.COM.BR

